BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.

15 Wall Street research analysts have issued 12 month price targets for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $83.00 to $200.00. On average, they expect the company's stock price to reach $119.39 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.

BioMarin Pharmaceutical's stock was trading at $103.49 at the start of the year. Since then, BMRN stock has increased by 12.8% and is now trading at $116.71.
View the best growth stocks for 2023 here.

BioMarin Pharmaceutical saw a decrease in short interest in January. As of January 15th, there was short interest totaling 6,700,000 shares, a decrease of 35.3% from the December 31st total of 10,360,000 shares. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is presently 4.3 days. Currently, 3.7% of the company's stock are short sold.
View BioMarin Pharmaceutical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BMRN earnings forecast.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings results on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a net margin of 4.18% and a trailing twelve-month return on equity of 2.50%. The firm's revenue for the quarter was down 14.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.29 EPS.

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Parnassus Investments LLC (1.26%), Fort Washington Investment Advisors Inc. OH (0.62%), Manning & Napier Group LLC (0.47%), Assenagon Asset Management S.A. (0.38%), Sumitomo Mitsui Trust Holdings Inc. (0.32%) and Scout Investments Inc. (0.30%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends.

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BMRN stock can currently be purchased for approximately $116.71.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $21.65 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.42 on an earnings per share basis.

The company employs 3,045 workers across the globe.

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.